Intravenous Alfacalcidol Once Weekly Pulse Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients

Figures & data

Table 1. Demographic characteristics of the studied patients

Characteristic	Group 1 (n = 18)	Group 2 (n = 18)	p
Age (years) (mean ± SD)	48.83 ± 14.58	48.89 ± 20.34	0.99
Sex [n (%)]
Male	11 (61.1)	11 (61.1)	1.00
Female	7 (38.9)	7 (38.9)
Duration of dialysis (months) (mean ± SD)	52.61 ± 15.4	52.21 ± 13.6	0.45
Original kidney disease [n (%)]
Diabetic nephropathy	2 (11.1)	6 (33.3)
Hypertensive glomerulosclerosis	0 (0)	2 (11.1)
Diabetic and hypertensive kidney disease	10 (55.6)	4 (22.2)
Chronic glomerulonephritis	1 (5.6)	2 (11.1)
Chronic interstitial nephritis	1 (5.6)	1 (5.6)
Unknown	4 (22.2)	2 (11.1)
Hypoplastic kidneys	0 (0)	1 (5.6)

Table 2. Biochemical parameters for the studied patients

Parameter	Group 1 (n = 18)	Group 2 (n = 18)	p
Intact parathyroid hormone (pmol/L)
Baseline (mean ± SD)	86.00 ± 33.20	83.64 ± 32.12	0.83
Post-treatment (mean ± SD)	31.04 ± 7.77	33.09 ± 11.33	0.53
Alkaline phosphatase (IU/L)
Baseline (mean ± SD)	227.94 ± 129.86	285.39 ± 232.36	0.92
Post-treatment (mean ± SD)	163.17 ± 95.29	202.56 ± 165.84	0.89
Serum-corrected calcium (mmol/L)
Baseline (mean ± SD)	2.24 ± 0.10	2.17 ± 0.20	0.24
Post-treatment (mean ± SD)	2.29 ± 0.12	2.19 ± 0.20	0.07
Serum phosphorus (mmol/L)
Baseline (mean ± SD)	1.50 ± 0.22	1.51 ± 0.31	0.86
Post-treatment (mean ± SD)	1.51 ± 0.21	1.54 ± 0.26	0.71
Calcium–phosphorus product (mmol^2/L^2)
Baseline (mean ± SD)	3.35 ± 0.47	3.30 ± 0.74	0.79
Post-treatment (mean ± SD)	3.46 ± 0.55	3.38 ± 0.71	0.78

Notes: Reference range for 1 – intact parathyroid hormone (1.60–9.30 pmol/L); 2 – alkaline phosphatase (26–120 IU/L); 3 – serum calcium (2.10–2.60 mmol/L); 4 – serum phosphorus (0.80–1.60 mmol/L).

Figure 1. Response of intact parathyroid hormone (i-PTH) to alfacalcidol.

Figure 2. Response of alkaline phosphatase (ALP) to alfacalcidol.